All these kinases displayed mutations in more than 6% of CDX2-suppressed colorectal cancers in the TCGA cohort, and some receptor tyrosine kinases, including EGFR, ERBB3, ERBB4, RET, ROS1, and ALK, showed even higher mutation rates in these cancers (Figure 1). The gene discussed is ROS1; the disease is cancer.